Novo Nordisk's experimental pill amycretin shows promising results in early trials, with participants losing up to 24.3% of body weight by targeting two hunger hormones.

Novo Nordisk's growth hormone therapy Sogroya gets EMA nod for expanded use in kids May 26, 2023 5:11 AM ET Novo Nordisk A/S (NVO) Stock By: Ravikash Bakolia, SA News Editor 6 Comments ...

The phase 3 clinical trial compared eftansomatropin alfa, Genexine’s long-acting growth hormone, to Novo Nordisk’s daily injectable Norditropin in children with growth hormone deficiency.

Novo Nordisk reports phase 3 data showing weekly Sogroya matched or outperformed daily hormone therapy in multiple pediatric growth disorders.

Novo is also testing a subcutaneous form of amycretin that, like Wegovy, would be delivered by regular injection. The early stage trial is ongoing and data is expected to be released in 2025.

Novo Nordisk introduced the growth hormone Norditropin in 1988 and launched its first prefilled injection pen, Norditropin Nordiflex, in 2004, the company said.